Kazia Therapeutics Limited
ASX Code
KZA
Sector
Pharmaceuticals- Biotechnology & Life Sciences
Investor Centre
https://www.kaziatherapeutics.com/investorcentre
Website
https://www.kaziatherapeutics.com/home
About
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Kazia'spipeline includes two clinical-stage drug development candidates, and they are working to develop therapies across a range of oncology indications. Kazia's lead program is paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib entered a phase II clinical trial in 2018. Interim data was reported in April 2020, and further data is expected in 2H 2020. Paxal
News
Research
| A Laser-Like Focus on Adding Value -5 Data Readouts in 9-Months | |
| SNO Presentations: Late-Interim Results from Phase II GBM & Phase I DIPG Studies Released | |
| Cantrixil Iicensed To Oasmia Pharmaceuticals & Kazia Shareholders Learn a Positive Lesson About Kazia | |
| Do Two A+ Deals Foreshadow THE DEAL? | |
| Another Deal – Kazia Inlicences New Anti-Cancer Med From Highly Impressive Partner | |
| Biopharmas Hit, but Buying Opportunities Created Antisense (ANP) & Kazia (KZA), Two Companies To Build Your Biopharma Portfolio Around | |
| Paxalisib Misses AGILE Hurdle, but Very Significant Value Remains |